PCSA is the ticker symbol for Processa Pharmaceuticals, Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks PCSA with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is PCSA a good stock to buy?

PCSA is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/PCSA.

Where does 13F Pro source PCSA data?

All Processa Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Processa Pharmaceuticals, Inc. files with the SEC under CIK 1533743. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Processa Pharmaceuticals, Inc. PCSA

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.5M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Top Institutional Holders

as of Q2 2026

$498.3K total

Connective Capital Management, LLC

$163.7K+20.6%

Stonepine Capital Management, LLC

$105.6K0.0%

GEODE CAPITAL MANAGEMENT, LLC

$42.4K-11.3%

CITADEL ADVISORS LLC

$40.9KNew

StoneX Group Inc.

$29.6KNew

XTX Topco Ltd

$25.5KNew

JANE STREET GROUP, LLC

$25.5KNew

VANGUARD CAPITAL MANAGEMENT LLC

$24.4K0.0%

VANGUARD FIDUCIARY TRUST CO

$20.8K0.0%

UBS Group AG

$15.0K+207.9%

Tower Research Capital LLC (TRC)

$4.8K+172.2%

JONES FINANCIAL COMPANIES LLLP

$130.0%

See all 12 institutional holders →

Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026

EDGAR

EPS (Diluted)

Q2 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/PCSA

Earnings Per Share

13fpro.ai/company/PCSA

Loading ratio trend…

PCSA key financials by period

Reported revenue, net income and operating margin by fiscal year, from Processa Pharmaceuticals, Inc.'s annual filings on SEC EDGAR.

Processa Pharmaceuticals, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2016	10-K	$5.0K	$-1.9M	—
FY 2015	10-K	$113.4K	$-3.4M	—
FY 2014	10-K	$107.2K	$-4.5M	—
FY 2013	10-K	$312.5K	$-3.1M	—
FY 2012	10-K	$192.1K	$-2.4M	—

Source: PCSA filings on SEC EDGAR →

About Processa Pharmaceuticals, Inc. (PCSA): stock profile, AI score and financials

Processa Pharmaceuticals, Inc. (PCSA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. PCSA is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.5m in revenue and is scored on the micro-cap board instead. Top institutional holders of PCSA by reported 13-F value include Connective Capital Management, Stonepine Capital Management, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. PCSA trades on the Nasdaq exchange and files with the SEC under CIK 1533743. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PCSA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Processa Pharmaceuticals, Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1533743 →